compound kushen injection

Drug Overview

Compound Kushen Injection (CKI) is a traditional Chinese medicine (TCM)-based therapeutic agent that has been modernized for use in integrative oncology and supportive cancer care. Unlike conventional chemotherapy drugs, it is derived entirely from natural plant sources and is used both as a standalone treatment and in combination with standard cancer therapies. It represents a meaningful bridge between centuries-old herbal medicine and contemporary cancer management.

CKI is built around two primary active alkaloids, Matrine and Oxymatrine, extracted from the roots of Sophora flavescens and Sophora subprostrata, plants with a long history in traditional medicine. Key identifying details for this agent are listed below:

• Generic Name: Compound Kushen Injection (CKI); principal active constituents are Matrine and Oxymatrine
• US Brand Names: None officially recognized in the United States
• Drug Class: Botanical Anticancer Agent; Traditional Chinese Medicine Injectable; Integrative Oncology Supportive Therapy
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Not FDA-approved. CKI is clinically approved and widely used in China. It remains investigational in the United States and Europe and is accessible only through approved research or clinical trial settings

What Is It and How Does It Work? (Mechanism of Action)

Compound Kushen Injection is distinguished by its ability to act on multiple biological targets simultaneously, a characteristic that sets it apart from most single-target oncology drugs. Its two core alkaloids, Matrine and Oxymatrine, work together through several interconnected molecular pathways to slow cancer growth, support immune function, and reduce treatment-related harm.

CKI activates the body’s natural programmed cell death process, known as apoptosis, within cancer cells. It achieves this by increasing the activity of pro-apoptotic proteins such as Bax and Caspase-3, while simultaneously suppressing the survival protein Bcl-2. This molecular imbalance pushes cancer cells toward self-destruction. At the same time, CKI disrupts two key signaling networks that tumors rely on for uncontrolled growth, specifically the PI3K/Akt/mTOR pathway and the MAPK/ERK pathway, effectively cutting off the internal instructions that tell cancer cells to keep dividing.

CKI also halts the cancer cell cycle at the G0/G1 phase, preventing cells from completing the replication process needed to multiply. Beyond direct tumor effects, CKI reduces tumor angiogenesis by suppressing Vascular Endothelial Growth Factor (VEGF), the protein tumors use to build new blood vessels and expand their nutrient supply. Without this blood supply, tumor growth is significantly constrained. Additionally, CKI modulates immune function by enhancing the activity of natural killer cells and T-lymphocytes, and reduces systemic inflammation by downregulating key inflammatory mediators including TNF-alpha, IL-6, and NF-kB.

FDA Approved Clinical Indications

CKI does not currently hold FDA approval for any indication. It is officially approved and widely administered in China and is under active international investigation for the following conditions.

Oncological Uses (Approved in China / Investigational Internationally):

• Lung cancer, including both non-small cell and small cell subtypes, used alongside chemotherapy
• Hepatocellular carcinoma (liver cancer), used to slow tumor progression and support liver function
• Gastric cancer, administered as adjunct therapy to enhance chemotherapy effectiveness
• Colorectal cancer, studied for tumor response and quality-of-life improvement
• Cervical cancer, used in combination with radiotherapy and chemotherapy protocols
• Breast cancer, investigated for anti-proliferative effects on tumor cells
• Leukemia, studied for its ability to promote apoptosis in malignant blood cells

Non-Oncological Uses (Investigational):

• Chronic viral hepatitis, particularly Hepatitis B, where Oxymatrine has demonstrated antiviral activity
• Inflammatory conditions, used in integrative medicine to manage elevated systemic inflammation
• Cardiac arrhythmia, where Matrine has been studied for mild antiarrhythmic properties

Dosage and Administration Protocols

CKI is administered exclusively under the supervision of a qualified physician in a hospital or approved clinical trial setting. Dosing follows established Chinese clinical guidelines and active trial protocols.

Clinical Efficacy and Research Results

Research activity on CKI has expanded considerably between 2020 and 2025, with growing interest in its role as a complement to standard oncology regimens.

In lung cancer, systematic reviews and meta-analyses have demonstrated that patients receiving CKI alongside platinum-based chemotherapy showed improved objective response rates and better disease control compared to chemotherapy alone. Patients also reported meaningful improvements in quality-of-life measures. In hepatocellular carcinoma, studies combining CKI with transarterial chemoembolization (TACE) suggest improved tumor control and preservation of liver function markers relative to TACE alone. Research consistently shows that CKI helps maintain or restore immune cell counts, including CD4+ T-lymphocytes and natural killer cells, in patients undergoing chemotherapy.

This is clinically relevant because sustained immune function during treatment is associated with improved patient outcomes. Controlled trials have also indicated lower rates of severe nausea, vomiting, and bone marrow suppression in patients receiving CKI alongside chemotherapy, pointing to a meaningful supportive care benefit. It should be noted that a significant portion of available evidence originates from Chinese clinical settings with variable methodology. Larger, multi-center randomized controlled trials conducted in Western populations are still needed to validate these findings to international standards.

Safety Profile and Side Effects

CKI does not carry an FDA-issued Black Box Warning, as it is not FDA-approved. However, clinicians should be aware that serious hypersensitivity reactions, including anaphylaxis, have been reported with intravenous administration. Emergency resuscitation equipment must be available during every infusion session.

Common Side Effects (greater than 10%):

• Mild fever or chills, often occurring at the start of infusion and typically resolving without intervention
• Injection site discomfort including mild pain, redness, or vein irritation
• Nausea or mild gastrointestinal upset, generally manageable without discontinuation
• Dizziness or lightheadedness, particularly during or immediately following infusion
• Skin flushing or mild rash in a subset of patients

Serious Adverse Events:

• Anaphylaxis or severe allergic reaction, which is rare but documented and requires immediate medical intervention
• Elevated liver enzymes indicating hepatotoxicity, requiring regular monitoring in patients with pre-existing liver conditions
• Rare cardiovascular effects including palpitations or changes in heart rhythm, particularly associated with rapid infusion rates

Management Strategies:

If mild fever or chills develop, the infusion rate should be slowed and the patient monitored closely. Antihistamines may be administered for skin reactions. In the event of any sign of anaphylaxis, the infusion must be stopped immediately and emergency treatment initiated with epinephrine, antihistamines, and corticosteroids as appropriate. Liver function tests including ALT, AST, and bilirubin should be assessed before and throughout the treatment course. Cardiac monitoring is advised for patients with a known history of heart disease.

Research Areas

CKI is not currently incorporated into formal stem cell transplantation protocols. However, several emerging research directions reflect its growing relevance in modern oncology science. Researchers are investigating whether CKI can enhance the effectiveness of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors by improving the immune environment surrounding the tumor. Early laboratory and small-scale clinical findings suggest a potential synergistic effect. CKI is also being studied for its ability to modify the tumor microenvironment, potentially making tumors more susceptible to immune-mediated attack. Additionally, ongoing research is examining whether CKI can sensitize certain tumors to standard chemotherapy agents, which may allow for reduced chemotherapy dosing with equivalent or improved outcomes, thereby lowering overall treatment toxicity for patients.

Patient Management and Practical Recommendations

Pre-Treatment Tests to Be Performed:

• Complete blood count to assess baseline immune and blood cell status
• Liver function tests including ALT, AST, and bilirubin prior to initiating CKI
• Kidney function tests including serum creatinine and estimated glomerular filtration rate
• Thorough allergy history review, particularly for patients with known sensitivities to botanical agents
• Baseline electrocardiogram for patients with a history of cardiac conditions
• Serum pregnancy test for women of childbearing age, as CKI is not recommended during pregnancy

Precautions During Treatment:

• CKI must always be diluted prior to infusion and must never be administered as an undiluted intravenous push
• Infusion should begin at a slow rate with gradual increases to allow early detection of hypersensitivity
• Medical staff should observe the patient for at least 30 minutes at the start of each infusion session
• CKI should not be co-administered in the same IV line with other medications without confirmed compatibility

Do’s and Don’ts:

• Inform your doctor about all medications, supplements, and herbal products currently being taken
• Attend all scheduled infusion appointments and follow-up laboratory evaluations
• Report any unusual symptoms such as itching, shortness of breath, or dizziness immediately during infusion
• Maintain adequate hydration before and after each session
• Do not self-administer or adjust the dosage without direct physician guidance
• Do not use CKI as a substitute for established, evidence-based cancer treatments
• Do not bring pregnant family members or young children to infusion appointments
• Do not ignore new or unexpected symptoms between sessions; contact your care team promptly

Legal Disclaimer

The information provided in this guide is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. Compound Kushen Injection is not approved by the United States Food and Drug Administration or the European Medicines Agency for any clinical indication and is accessible in Western markets only through approved investigational or clinical trial frameworks. Its clinical use is recognized under Chinese regulatory standards. All treatment decisions must be made exclusively by a qualified and licensed healthcare professional in accordance with the patient’s individual medical history, current clinical condition, and applicable local regulations. This content should not be used as a substitute for professional medical consultation.